Clonazepam
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
Clonazepam: From Its Listed Uses to Restless Legs Syndrome
One-Sentence Summary
Clonazepam is a benzodiazepine that is currently marketed in the US, but the supplied data does not record its original approved indication. The TxGNN model predicts it may be effective for restless legs syndrome (RLS). There are no registered clinical trials and 20 publications for this indication, including a 2025 AASM guideline, a Cochrane review, and two small randomized trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the supplied data (all license entries have empty indication text) |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed licenses are ANDAs, i.e., generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Clonazepam is a GABA-A positive allosteric modulator. Detailed mechanism-of-action data is not available in the supplied record. The mechanism below comes from the analysis of the prediction rather than from a drug-level record.
Clonazepam may reduce sleep fragmentation and arousals caused by periodic limb movements. RLS often disrupts sleep, so a sleep-related symptomatic benefit is plausible. This fits the literature, which describes benzodiazepines including clonazepam as long-used for RLS and periodic limb movements in sleep. One survey cited in the pack reports that about 25% of treated RLS patients receive benzodiazepines.
Clonazepam does not act on the dopaminergic or iron pathways thought to drive RLS. Any benefit is therefore likely to be symptomatic rather than disease-modifying. The very high TxGNN score cannot be checked against known original-indication pharmacology because that data is missing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6380197 | 1984 | RCT (double-blind crossover, n=6) | Acta Neurol Scand | Clonazepam significantly improved subjective sleep quality and leg dysaesthesia versus placebo. Long-term efficacy needs confirmation. |
| 31942156 | 2019 | RCT (open-label) | J Mid-life Health | Compared clonazepam with nortriptyline in women over 40 with RLS, looking at rate, frequency and severity. Results are not in the supplied abstract. |
| 39324694 | 2025 | Clinical practice guideline | J Clin Sleep Med | AASM guideline on treating RLS and periodic limb movement disorder in adults and children. The specific clonazepam recommendation is not in the supplied text. |
| 28319266 | 2017 | Systematic review | Cochrane Database Syst Rev | Reviews benzodiazepines for RLS. Notes that clonazepam is used for RLS symptoms. Conclusions are not in the supplied abstract. |
| 36692194 | 2023 | Systematic review and meta-analysis | J Clin Sleep Med | Assesses which drug classes suppress periodic limb movements in RLS. Design details are unclear from the supplied text. |
| 38708125 | 2024 | Review | Tremor Other Hyperkinet Mov | Historical overview of benzodiazepines in RLS and periodic limb movements in sleep. Found 17 articles on clonazepam in RLS. |
| 18925578 | 2008 | Evidence-based review | Mov Disord | Movement Disorder Society task force graded the efficacy of RLS treatments. Its grading of clonazepam is not in the supplied text. |
| 24363103 | 2014 | Review | Neurotherapeutics | Overview of RLS treatment, which has changed considerably in recent years. |
| 9444111 | 1997 | Review | ANNA J | Clonazepam is one of several agents used for RLS in end-stage renal disease. Its pharmacokinetics suggest safety with altered kidney function. |
| 3510520 | 1986 | Review | Am Fam Physician | Clinical overview of RLS. Clonazepam is mentioned as a treatment option. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA077856 | Clonazepam (Aphena Pharma Solutions) | Tablet | Not stated in supplied data |
| ANDA077194 | Clonazepam (Teva) | Orally disintegrating tablet | Not stated in supplied data |
| ANDA074569 | Clonazepam (Clinical Solutions Wholesale) | Tablet | Not stated in supplied data |
| ANDA077856 | Clonazepam (Bryant Ranch Prepack) | Tablet | Not stated in supplied data |
| ANDA077856 | Clonazepam (PD-Rx Pharmaceuticals) | Tablet | Not stated in supplied data |
Safety Considerations
Please refer to the package insert for safety information.
The pack’s analysis also flags the general benzodiazepine risks of dependence, tolerance and cognitive effects. These risks weigh against long-term use in a chronic condition such as RLS.
Conclusion and Next Steps
Decision: Hold
Rationale: The literature for RLS is substantial and includes a 2025 guideline, a Cochrane review, and two small randomized trials. However, there are no registered clinical trials, and the RCT evidence is small and dated. The mechanism suggests only symptomatic, sleep-related benefit. The original indication, package-insert warnings and contraindications are all missing, so safety screening cannot proceed.
Two other predicted indications are weaker: insomnia (only indirect evidence) and trigeminal nerve neoplasm (no plausible mechanism). They are not recommended for advancement.
To proceed, the following is needed:
- The FDA package insert (warnings, contraindications, approved indications), which is a blocking gap for safety screening
- Confirmed mechanism-of-action and original-indication data from DrugBank
- Extraction of the specific clonazepam recommendations from the AASM 2025 guideline, the Cochrane review and the MDS review
- A dependence, tolerance and long-term safety assessment for chronic RLS use, compared with first-line alternatives
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.